




# Psychedelic Medicine Task Force

# Welcome Psychedelic Medicine Task Force members!

Please use this time to test your Zoom meeting controls located at the bottom of the screen:



Access **Mural** via the link sent to you in your meeting invitation. Only members have access to this shared workspace. Once on the site, minimize the screen for later use during the meeting.

## MDH staff

- **Kari Gloppen**, Epidemiologist  
Supervisor, Injury and Violence  
Prevention Section
- **Dr. Caroline Johnson**, Psychedelic  
Medicine Scientific Researcher

## Task Force leadership

- Dr. Jessica Nielson, Chair
- Bennett Hartz, Vice-Chair
- Paula DeSanto, Work Group Chair

## MAD staff

- Jessica Burke, Senior Management  
Consultant
- Nick Kor, Senior Management Consultant
- Stacy Sjogren, Senior Management  
Consultant

# Welcome meeting observers

**Thank you** for your interest in the work of the  
Psychedelic Medicine Task Force!

This meeting will not be recorded. **Minutes will be posted on the task force's website** along with other materials for this meeting:

<https://www.health.state.mn.us/people/psychmed/index.html>

[health.psychedelictmemedicine@state.mn.us](mailto:health.psychedelictmemedicine@state.mn.us)

The Psychedelic Medicine Task Force was established to advise the legislature on the legal, medical, and policy issues associated with the legalization of psychedelic medicine in the state. For purposes of this work, “psychedelic medicine” means MDMA, psilocybin, and LSD.


## Scientific Research

1. Survey existing studies in the scientific literature on the therapeutic **efficacy** of psychedelic medicine in the treatment of mental health conditions, including depression, anxiety, post-traumatic stress disorder, bipolar disorder, and **any other mental health conditions and medical conditions** for which a psychedelic medicine may provide an **effective** treatment option.
2. Compare the efficacy of psychedelic medicine in treating the conditions described [above] with the efficacy of treatments currently used for these conditions.

Develop a comprehensive plan that covers:

1. statutory changes necessary for the legalization of psychedelic medicine.
2. state and local regulation of psychedelic medicine
3. federal law, policy, and regulation of psychedelic medicine, with a focus on retaining state autonomy to act without conflicting with federal law, including methods to resolve conflicts.
  - Such as seeking an administrative exemption to the federal Controlled Substances Act under United States Code, title 21, section 822(d), and Code of Federal Regulations, title 21, part 1307.03; seeking a judicially created exemption to the federal Controlled Substances Act; petitioning the United States Attorney General to establish a research program under United States Code, title 21, section 872(e); using the Food and Drug Administration's expanded access program; and using authority under the federal Right to Try Act
4. Education of the public on recommendations made to the legislature and others about necessary and appropriate actions related to the legalization of psychedelic medicine in the state.

# Work cadence






# Today's agenda

- Approve September and October meeting summaries
- Share member-collected feedback
- Finalize task force report content
- Looking forward: post task force
- Small group discussions and debrief


# Task Force Status Update – November 2024

Dr. Jessica Nielson | Task Force Chair

# Timeline: decision flow chart



# Timeline: decision flow chart



# Finalizing task force report content

# Report development

- Timeline
  - MAD copyediting (10/24)
  - **MDH copyediting (11/8)**
- Report overview
  - Body of report: 60 pages
  - 15 appendices
- Feedback from MAD
- Next steps

# Looking forward: post task force

# What comes next?

- What happens after the final task force meeting next month?
- These conversations will not affect the content of the report.
- We will break into four groups, then reconvene to talk more as a full group.



# Small group topics

- What are the elements of a formal public education program and who might best be responsible for it in the near future?
- Where could a psychedelic medicine program live successfully within the structure of state government?
- How could the cost of psychedelic medicine be affordable for people who need it?
- How could interested task force members and their communities continue working together to advocate for this work?

## Next steps and adjournment

- **Opportunity for member feedback:** please leave your feedback in Mural.
- **Questions between meetings:** contact Jess Burke ([jessica.burke@state.mn.us](mailto:jessica.burke@state.mn.us))
- **FINAL meeting:** Monday, December 2, 2024, 9:30 am